Dianthus Therapeutics
DNTH
DNTH
165 hedge funds and large institutions have $2.02B invested in Dianthus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 75 increasing their positions, 27 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
30.93% less ownership
Funds ownership: 145.48% → 114.56% (-31%)
65% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $3.03M
Holders
165
Holding in Top 10
8
Calls
$1.05M
Puts
$3.03M
Top Buyers
| 1 | +$32.4M | |
| 2 | +$22.3M | |
| 3 | +$20.2M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.9M |
Top Sellers
| 1 | -$48.7M | |
| 2 | -$46.4M | |
| 3 | -$45.4M | |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$42.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34M |
